Blockchain Registration Transaction Record

NRx Re-files KETAFREE™ Application, Advances Safer Ketamine Treatments

NRx Pharmaceuticals re-files ANDA for KETAFREE™ preservative-free ketamine and advances NRX-100 for suicidal depression. Learn about safer IV formulations and breakthrough depression treatments.

This development matters because it addresses critical safety concerns in ketamine treatments while expanding access to mental health care. The elimination of neurotoxic preservatives like benzethonium chloride represents a significant advancement in patient safety, particularly for individuals requiring repeated ketamine infusions for conditions like treatment-resistant depression. With mental health crises and suicide rates at alarming levels globally, NRx's preservative-free formulations and specialized depression treatments could provide safer, more effective options for patients who have exhausted conventional therapies. The company's progress comes amid growing ketamine shortages and increasing recognition of ketamine's therapeutic potential, making these developments timely and potentially life-saving for patients with severe depression and suicidal ideation.